What 'cell-free' actually means — and why it matters to you

Two philosophies sit at the heart of modern cartilage repair. The first introduces a living biological ingredient — stem cells extracted from bone marrow or fat tissue, sometimes expanded in a laboratory — and places them directly into the damaged area to drive healing. The second takes a different approach: place a scaffold, step back, and let the body's own progenitor cells migrate in and do the building work themselves.

ChondroFiller injection belongs to the second camp. The injectable collagen matrix contains no harvested or manufactured cells; it gels at the defect site within minutes and acts as a chemotactic scaffold — a recruiting signal — for the patient's own stem-like progenitor cells. Stem cell therapies, by contrast, require a separate tissue harvest, and in protocols involving laboratory cell expansion, a waiting period before delivery is possible.

That biological difference cascades into practical consequences: how many steps are involved, how long the path from treatment to recovery takes, and what the overall cost looks like. Both approaches, when successful, aim to produce hyaline-like cartilage — the genuine load-bearing tissue of a healthy joint — rather than the fibrocartilage that microfracture typically yields.

This article focuses on ChondroFiller injection as the protagonist. The question is not which technique is inherently superior in the abstract, but which better fits a given patient's defect, joint, timetable, and clinical circumstances — and that distinction begins with understanding what 'cell-free' actually means at the point of treatment.

How the ChondroFiller injection works

The product arrives pre-prepared in a two-chamber syringe — one chamber holding ultrapure Type I collagen, the other a neutralising solution that initiates the gelling reaction on mixing. Delivered as an ultrasound-guided outpatient injection, the liquid conforms to the cartilage defect before firming into a dimensionally stable hydrogel within approximately three to five minutes. No operating theatre is required, and treatment takes place in a single clinic visit.

Once set, the gel acts as a chemotactic matrix. Its collagen architecture generates a molecular signal that draws the patient's own progenitor cells — including circulating mesenchymal stem-like cells — towards the defect. Those cells migrate in, proliferate within the scaffold, and, over weeks and months, differentiate into new cartilage tissue through matrix-induced chondrogenesis: the body's repair process directed by the scaffold's biological cues rather than by introduced cells.

A 2025 ex vivo osteochondral model illustrated this mechanism directly: scaffolds treated with ChondroFiller alone showed a 2.4-fold increase in DNA content by day 14, reflecting substantial endogenous cell recruitment driven by the scaffold structure without any exogenous cell input. Because no preliminary biopsy or cell harvest is needed, there is no waiting period between referral and treatment — the single-stage, outpatient nature of the injection is a direct consequence of the biology, not a procedural workaround.

What stem cell therapy actually involves for a patient

Deciding what stem cell therapy actually involves — in practice, for a patient with a focal cartilage defect — depends substantially on which protocol is being used.

The most accessible cell-based option is a same-day concentrated cell injection: bone marrow aspirate concentrate (BMAC) or adipose-derived cells are harvested, processed, and delivered in a single visit. This adds one meaningful procedural step — typically a bone marrow draw from the iliac crest or a small fat sample — but avoids a separate return appointment. More resource-intensive approaches, such as matrix-induced autologous chondrocyte implantation (MACI), require a cartilage biopsy followed by several weeks of specialist laboratory cell culture, cold-chain handling, and a second procedure for reimplantation. The total course from biopsy to treatment can span two to three months.

There is no published head-to-head randomised controlled trial directly comparing ChondroFiller injection with any stem cell protocol. Any comparison between the two routes draws on separate trial datasets rather than direct experimental evidence — a limitation worth holding in mind before weighing one against the other on outcome grounds.

What the 2025 ex vivo osteochondral model did show — alongside the scaffold's cell-recruitment signal described in the previous section — was that groups receiving additional mesenchymal stem cells produced greater collagen and glycosaminoglycan (GAG) deposition than scaffold alone. That is a genuine biological finding, not a trivial one. Whether the difference in tissue composition translates into measurably better long-term joint function remains untested in any powered clinical trial.

For patients who want the potential tissue-quality benefit of stem cells alongside the scaffold, a combination approach is documented in the UK private market: the 'Tri-Active' protocol, in which ChondroFiller injection is co-delivered with autologous stem cells, is priced at approximately £11,000 — compared with ChondroFiller injection alone as the baseline.

Outcomes and tissue quality: what the evidence shows

The functional outcome data available across ChondroFiller injection cohorts is consistent, though drawn from trials that are small by the standards of pharmaceutical research — none has enrolled more than 60 patients. Held with that context, the signals are meaningful: knee cohorts show an average IKDC improvement of approximately 30 points at 12 months, a gain that broadly matches the 30–35 point improvement reported for autologous chondrocyte implantation and MACI in comparable patient populations.

Where the difference becomes clinically significant is in the safety profile. Published series report a complication rate approaching zero and a reoperation rate of approximately 3–8% for ChondroFiller injection. ACI and MACI, by contrast, carry complication rates of up to 17% and reoperation rates reaching 37% — a substantially higher risk burden alongside comparable functional gains.

The hip and wrist datasets extend this picture beyond the knee. A hip cohort study (26 patients, up to five years of follow-up) found 17 of 21 evaluable patients achieved good or excellent results. A 2025 study of intra-articular distal radius fractures showed ChondroFiller-treated patients had significantly better cartilage quality scores — median Outerbridge grade 1.5 versus 3.0 in untreated controls (P=0.006) — confirming the approach is technically feasible across smaller joints.

On tissue quality, both ChondroFiller injection and cell-based approaches generate hyaline-like repair tissue, in contrast to the fibrocartilage that microfracture produces, which evidence suggests tends to deteriorate within two to three years. The ex vivo finding — discussed in the previous section — that MSC-augmented groups showed greater collagen and glycosaminoglycan deposition raises the possibility of a qualitative difference between cell-free and cell-based scaffolds. That signal has not yet been replicated in a powered clinical trial, and without head-to-head long-term data, it is not possible to say whether it translates into meaningfully better joint function.

Who is a suitable candidate — and who is not

Suitability for ChondroFiller injection — or any cell-based alternative — turns on three practical parameters: the extent of joint-wide disease, the size of the defect, and the joint involved.

Both pathways are designed for focal, isolated cartilage lesions in otherwise preserved joints. Neither is appropriate where osteoarthritis has spread across the whole joint surface. For patients being assessed in a hip, the Tönnis grading system provides a useful signal: published cohort data show that Tönnis grade 2–3 disease predicts consistently poor outcomes with ChondroFiller injection, making frank discussion about joint preservation versus replacement the more honest next step for those patients.

Defect size matters too. ChondroFiller injection accommodates lesions up to 6 cm² — broader than the historical ceiling of approximately 2 cm² for microfracture and broadly comparable to the 2–10 cm² range for MACI. Smaller, contained defects with healthy surrounding cartilage are the clearest indication.

The joint coverage available with ChondroFiller injection is a genuine advantage for patients who have been told their options are limited outside the knee. Published evidence and clinical series span the knee, hip, ankle, wrist, shoulder, elbow, and small hand joints.

The target patient is typically younger or active, with a traumatic or degenerative focal defect in a joint that retains reasonable surrounding cartilage integrity. Patients with advanced or diffuse joint disease fall outside the indication for both pathways.

Recovery, practical burden, and taking the next step

Choosing between a cell-free scaffold and a cell-based protocol is, in practice, also a choice about procedural burden. ChondroFiller injection requires no preliminary biopsy visit, no weeks of cell culture, and none of the cold-chain logistics that come with live-cell products — the treatment takes place in a single outpatient session under ultrasound guidance, with no risk of immune reaction from donor cells.

The recovery phase, however, demands genuine commitment. A 2024 biomechanical study found that the ChondroFiller scaffold does not protect the opposing cartilage surface under cyclic loading in the early post-treatment period, owing to its initial mechanical instability. Six weeks of protected weight-bearing — crutches or a brace — follows directly from that finding and is not negotiable. Patients should plan for this practically: work arrangements, home setup, and daily routines all need to account for it. Low-impact activity typically resumes at around four months, with full tissue integration continuing over twelve months or longer.

Patients who appear suitable based on the criteria covered — a focal, isolated defect in a joint with reasonable surrounding cartilage and no advanced osteoarthritis — still need a structured clinical assessment to confirm defect size, OA grade, and joint eligibility before committing to treatment. That assessment is the appropriate first step, not the last.

Liquid Cartilage™ is available in the UK at the London Cartilage Clinic on Harley Street, where Professor Paul Y. F. Lee leads the programme. Assessments can be booked through londoncartilage.com.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
4. [4] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
5. [5] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759